ADMA
ADMA Biologics, Inc. Healthcare - Biotechnology Investor Relations →
ADMA Biologics, Inc. (ADMA) closed at $14.32 as of 2026-03-20, trading 40.6% above its 200-week moving average of $10.19. The stock is currently moving closer to the line, down from 49.6% last week. With a 14-week RSI of 10, ADMA is in oversold territory.
A big spike in selling this week — 2.5x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.
Over the past 600 weeks of data, ADMA has crossed below its 200-week moving average 5 times. On average, these episodes lasted 78 weeks. The average one-year return after crossing below was -23.3%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $3.4 billion, ADMA is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at 35.6%, indicating strong profitability. The stock trades at 7.1x book value.
Share count has increased 7.2% over three years, indicating dilution.
Over the past 11.6 years, a hypothetical investment of $100 in ADMA would have grown to $124, compared to $402 for the S&P 500. ADMA has returned 1.9% annualized vs 12.8% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ADMA vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ADMA Crosses Below the Line?
Across 5 historical episodes, buying ADMA when it crossed below its 200-week moving average produced an average return of -12.6% after 12 months (median -16.0%), compared to +9.6% for the S&P 500 over the same periods. 20% of those episodes were profitable after one year. After 24 months, the average return was +95.4% vs +37.2% for the index.
Each line shows $100 invested at the moment ADMA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
ADMA has crossed below its 200-week MA 5 times with an average 1-year return of +-23.3% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Mar 2015 | Jun 2015 | 17 | 17.8% | -45.0% | +55.5% |
| Jul 2015 | Oct 2015 | 11 | 8.5% | -26.6% | +56.8% |
| Oct 2015 | Sep 2019 | 203 | 69.6% | -32.5% | +54.6% |
| Sep 2019 | Aug 2022 | 153 | 68.3% | -53.0% | +208.6% |
| Sep 2022 | Nov 2022 | 8 | 13.6% | +40.8% | +440.4% |
| Average | 78 | — | +-23.3% | — |
Frequently Asked Questions
Is ADMA below its 200-week moving average?
No. ADMA Biologics, Inc. (ADMA) is currently 40.6% above its 200-week moving average of $10.19. It would need to fall to $10.19 to cross below the line.
What is ADMA's 200-week moving average price?
ADMA Biologics, Inc.'s 200-week moving average is $10.19 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ADMA drops below its 200-week moving average?
ADMA has crossed below its 200-week moving average 5 times in our data. The average one-year return after these crossings was -23.3%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 78 weeks on average.
Is ADMA a good value right now?
Here's what our data says about ADMA as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 10 (oversold). Free cash flow is currently negative. Return on equity is 35.6%. Price-to-book is 7.1x. This is not a buy or sell recommendation — always do your own research.
How does ADMA compare to the S&P 500?
Over the past 11.6 years, $100 invested in ADMA would have grown to $124, compared to $402 for the S&P 500. That's 1.9% annualized vs 12.8% for the index. ADMA has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20